Between 2019 and 2023, chronic disease drug claims increased much faster among younger plan members compared to older generations, according to a new report by Sun Life. The report, which analyzed drug claims data of more than 3 million plan members over a five-year period, found across all age groups, nearly half (45.1 per cent) of […]
Treating obesity with all available evidence-based tools ultimately costs less than not treating it, according to panellists during a webinar hosted by Benefits Canada and sponsored by Eli Lilly Canada Inc. in collaboration with Obesity Canada. Dr. Akshay Jain (pictured right), a clinical and research endocrinologist, provided an overview of obesity — a chronic, progressive, […]
An article on employees’ views of employer-sponsored benefits plans was the most-read story on BenefitsCanada.com this past week. Here are the top five human resources, benefits, pension and investment stories of the last week: 1. Survey finds seven in 10 Canadian workers dissatisfied with their employer’s benefits plan 2. Claims for obesity, diabetes medications up in 2023: […]
The percentage of claimants filing claims for obesity drugs increased by 43 per cent in 2023, according to a new report by GreenShield. The report, which analyzed the insurer’s 2023 claims data, found diabetes medications saw a 13 per cent increase in cost, accounting for nine per cent of total drug costs in 2023. There […]
With lyrics adapted to the tune of ‘Magic’ by Scottish pop group Pilot, the melody of ‘Oh, Oh, Oh, Ozempic’ is splashed across U.S. televisions in a snappy advertising campaign. The commercial push is likely unnecessary. Ozempic, one of the brand names of a glucagon-like peptide-1 receptor agonist medication used to treat type 2 diabetes, […]
U.S. employers’ health benefits costs are expected to increase to nearly eight per cent for 2025, the highest amount in more than a decade, according to a new survey by Business Group on Health. The survey, which polled 125 large employers, found they’re planning to continue to absorb much of the increases at least for […]
With obesity now understood to be a chronic health condition, it’s time for plan sponsors to revisit their approach to weight loss medications, said Philippe Laplante, principal for pension and benefits at Eckler Ltd., during a session at Benefits Canada’s 2024 Vancouver Benefits Summit in May. The conversation about extending coverage to new, high-cost anti-obesity […]
Roughly a third (34 per cent) of employers in the U.S. are providing coverage for glucagon-like peptide-1 medications for both diabetes care and weight-loss management in 2024, up from 26 per cent in 2023, according to a new survey by the International Foundation of Employee Benefit Plans. However, the survey, which polled more than 270 U.S. employers, found more […]
An article detailing a stark increase in the use of obesity medications among Canadian employer-sponsored benefits plan members was the most-read article on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investment stories of the past week: 1. Claims for obesity drugs increased 42% in 2023, 92% since 2020: report 2. How […]
When considering whether to cover Wegovy, an obesity medication, it’s important for plan sponsors to weigh increased short-term costs with long-term savings, while considering alternative treatments that are also available, says Philippe Laplante, a principal at Eckler Ltd. Plan sponsors that decide to cover Wegovy, which launched in Canada last month, could see a significant cost […]